Ibrutinib in Combination with Nab-Paclitaxel and Gemcitabine for First-Line Treatment of Patients with Metastatic Pancreatic Adenocarcinoma: Phase 3 RESOLVE Study

Archive ouverte

Tempero, M. | Oh, D.-Y. | Tabernero, J. | Reni, M. | van Cutsem, E. | Hendifar, A. | Waldschmidt, D.-T. | Starling, N. | Bachet, J.-B. | Chang, H.-M. | Maurel, J. | Garcia-Carbonero, R. | Lonardi, S. | Coussens, L.M., M | Fong, L. | Tsao, L.C., C | Cole, G. | James, D. | Macarulla, T.

Edité par CCSD ; Elsevier -

International audience. Background: First-line treatment for metastatic pancreatic ductal adenocarcinoma (PDAC) includes nab-paclitaxel/gemcitabine. Ibrutinib, a Bruton's tyrosine kinase inhibitor, exhibits antitumor activity through tumor microenvironment modulation. The safety and efficacy of first-line ibrutinib plus nab-paclitaxel/gemcitabine treatment in patients with PDAC was evaluated.Patients and methods: RESOLVE (NCT02436668) was a phase 3, randomized, double-blind, placebo-controlled study. Patients (histologically-confirmed PDAC; stage IV diagnosis ≥6 weeks of randomization; Karnofsky performance score ≥70) were randomized to once-daily oral ibrutinib (560 mg) or placebo plus nab-paclitaxel (125 mg/m2) and gemcitabine (1,000 mg/m2). Primary endpoints were overall survival (OS) and investigator-assessed progression-free survival (PFS); overall response rate (ORR) and safety were assessed.Results: In total, 424 patients were randomized (ibrutinib arm, n=211; placebo arm, n=213). Baseline characteristics were balanced across arms. After median follow-up of 25 months, there was no significant difference in OS between ibrutinib plus nab-paclitaxel/gemcitabine vs placebo plus nab-paclitaxel/gemcitabine (median of 9.7 vs 10.8 months; P=0.3225). PFS was shorter for ibrutinib plus nab-paclitaxel/gemcitabine compared with placebo plus nab-paclitaxel/gemcitabine (median 5.3 vs 6.0 months; P<0.0001). ORRs were 29% and 42%, respectively (P=0.0058). Patients in the ibrutinib arm had less time on treatment and received lower cumulative dose for all agents compared to placebo arm. Most common grade ≥3 adverse events (AEs) for ibrutinib vs placebo arms included neutropenia (24% vs 35%), peripheral sensory neuropathy (17% vs 8%), and anemia (16% vs 17%). Primary reasons for any treatment discontinuation were disease progression and AEs.Conclusions: Ibrutinib plus nab-paclitaxel/gemcitabine did not improve OS or PFS for patients with PDAC. Safety was consistent with known profiles for these agents.

• Description
• Sujet/Public
• Outil
• Outil d'anticipation
• Mémoire et thèse
• Gestion